Compare Heron Therapeutics Inc (HRTX) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 245.8× Heron Therapeutics Inc's market cap, and iShares 3 7 Year Treasury Bond ETF is more actively traded (3,963,319 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| HRTX | IEI | |
|---|---|---|
Market Cap | $68.01M | $16.72B |
Volume | 1,891,941 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $120.72 |
52-Week Low | $0.27 | $113.17 |
Typical Hold Time | 35 Days | 43 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
IEI trades at $113.57 with minimal daily movement (+0.17%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling downward pressure, though oscillators suggest neutral momentum. Recent dividend payments of $0.37-0.38 per share demonstrate consistent shareholder returns. The stock faces headwinds from rising Treasury yields and bond market volatility, which could impact investor appetite for equities.
Outlook remains cautious as higher interest rates and bond market turbulence create challenging conditions. The bearish technical signals and neutral fundamental metrics suggest limited near-term upside potential. Key risks include continued bond market volatility and macroeconomic pressures, though consistent dividend payments provide some defensive characteristics for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
